A precise temperature control during hyperthermic intraperitoneal chemotherapy promises an early return of bowel...

Area of Science:

• Oncology
• Surgical Oncology
• Gastroenterology

Background:

• Hyperthermic intraperitoneal chemotherapy (HIPEC) is a standard treatment for peritoneal carcinomatosis (PC).
• Perfusion temperature during HIPEC is a critical factor influencing treatment efficacy.
• Fluctuations in temperature can negatively impact patient outcomes.

Purpose of the Study:

• To investigate the impact of stable perfusion temperature during HIPEC on bowel function recovery in patients with gastrointestinal malignancies and PC.
• To assess the correlation between stable HIPEC temperature and postoperative pain.
• To evaluate the effect of stable HIPEC temperature on overall survival.

Main Methods:

• A cohort of 59 PC patients undergoing cytoreductive surgery and HIPEC was divided into two groups: stable perfusion temperature and unstable perfusion temperature.
• Key metrics compared included time to flatus, defecation, and enteral nutrition initiation.
• Visual analogue scale (VAS) for pain and overall survival (OS) were also analyzed.

Main Results:

• Patients with stable HIPEC temperature experienced significantly earlier flatus (2.3 vs 3.9 days), defecation (5.2 vs 7.1 days), and enteral nutrition initiation (4.3 vs 6.7 days).
• The stable temperature group showed reduced VAS pain scores (4.5 vs 6.3).
• While the 5-year OS rate was higher in the stable group (17.8% vs 11.1%), this difference was not statistically significant.

Conclusions:

• Precise temperature control during HIPEC promotes earlier bowel function recovery.
• Stable perfusion temperature during HIPEC is associated with reduced postoperative pain.
• The current study cohort did not demonstrate a significant impact of stable HIPEC temperature on overall survival.